intermediate social and economic conditions, has a similar prevalence of gall stones at necropsy to that found in several English towns. However, the death rate from ischaemic heart disease in Scotland was 26% greater for males under 60 and 60% greater for females in the same age group. We do not have sufficient information to analyse statistically the relationship between gall stones and ischaemic heart disease, but these figures suggest that the negative correlation described by Dr Barker does not apply to this region.

ALAN FAICHNEY
L A DONALDSON

Department of Cardiac and
General Surgery,
Royal Infirmary,
Glasgow G4 0SF

¹ Donaldson LA, Busuttil A. *Br J Surg* 1975;62:26-32.
² World Health Organisation. *World health statistical Annual 1977*. Geneva: WHO, 1977:vol 1.

Incidence of malignant melanoma of the skin

SIR,—I would like to support the views expressed by Dr Peter Clough (12 January, p 112) in his recent letter concerning the association between malignant melanoma and arsenic in the soil. In a recent report¹ it was shown that, of 144 patients who had received medicinal arsenic in South-west Lancashire, 64 (44%) had premalignant keratoses and 17 (12%) had skin cancers. Chromosome studies performed on these patients showed significantly more chromosome abnormalities than in the controls, suggesting that arsenic is mutagenic as well as carcinogenic.

In an extended similar study of 481 subjects, 150 have died, 40 with malignant tumours of the skin or internal organs, including one malignant melanoma.

SUSAN EVANS

University Department of Medicine,
Liverpool L14 3LB

¹ Evans S. *Br J Derm* 1977;97, suppl 15:13-4.

ECT: balancing risks and benefits

SIR,—The Royal College of Psychiatrists several years ago published a memorandum on the use of electric convulsive therapy (ECT), in which it is implicit that the treatment is given under intravenous anaesthetic and muscle-relaxant drugs. It may not be generally realised that the anaesthetic is given solely to protect the patient from the unpleasant sensation of suffocation from paralysis of the respiratory muscles due to the effect of the muscle-relaxant drugs that are routinely used in general surgery. These are given, of course, to prevent the occasional fractures (mainly of the vertebrae) that used to occur when the ECT was given unmodified. The passage of the current required to start the convulsion does itself produce instantaneous loss of consciousness and a retrograde amnesia, usually only of a few seconds' duration, but sufficient to prevent the patient from knowing anything about the actual treatment.

The Royal College's memorandum on ECT made no mention of unmodified ECT, as it was rightly assumed that under all normal circumstances the treatment would always be given with anaesthetic and muscle relaxants. As strongly urged by the Faculty of Anaesthetists, the injections are supervised by an anaesthetist, though inevitably in some

hospitals or clinics a second psychiatric specialist experienced in anaesthetic techniques may actually give the injection. It is conceivable that there could be medical contraindications to the use of anaesthetics or muscular relaxants, or both, and yet the ECT be urgently needed to control the patient's behaviour. In these circumstances it would, of course, need the clinical judgment of the psychiatrist in charge of the case to decide whether to proceed after due consultation. There might also be situations in which anaesthetists are not available at short notice, or even a second psychiatrist experienced in anaesthetic techniques. Another possibility is that the patient has no usable veins, so that it might be more humane to proceed with unmodified treatment, the nursing staff itself receiving instruction on how to hold the patient. Again it would be a matter for the clinical judgment of the consultant whether in those circumstances he would be justified in going ahead without the modifications.

The current practice of ECT in this country is at the moment being investigated by the Royal College of Psychiatrists with a grant from the Department of Health and Social Security. It is hoped that this will show among other matters how many ECT treatments are usually given in a course, the usual clinical indications for its use, the incidence of complications and side effects, etc. As in the rest of clinical practice, the hazards of treatment have always to be balanced against the risks of continuing illness. It can be argued that withholding ECT from some patients—for example, the suicidally depressed—could amount to negligence.

DESMOND POND
President, Royal
College of Psychiatrists

London SW1X 8PG

Services for the mentally handicapped

SIR,—Now that the benefits of different types of services for the mentally handicapped are being considered (12 January, p 123), it seems justifiable to again ask if improvements should be based on the specialty of "mental handicap." It continues to be difficult to attract people to work in this field and the need becomes no less urgent. The objectives are clear: giving a high priority to prevention, treating mental handicap when feasible, and enabling the mentally handicapped to lead as normal a life as possible. Many of the problems are social and educational rather than medical, and an increasing contribution is being made from all these services.

Perhaps a change of attitude towards the medical component is needed. Will it ever be possible to provide sufficient consultants in mental handicap? It is recognised that age presents special medical problems, but is it also necessary to divide medical care according to the intelligence quotient? Cannot the medically handicapped be regarded as individuals who require special social and educational help, but have the same medical needs as anyone else? In paediatrics the problems are likely to be more varied than among children in general, and many will require help from those working in the paediatric subspecialties. In particular, the child who is mentally handicapped will be more than usually liable to emotional and behaviour disorders. So child psychiatrists will be particularly involved in the

care of such children, which will only be possible if extra resources are provided.

The problems are more difficult among adults who are mentally handicapped as fewer can be cared for at home. This may mean that the organisation of the services required will be the responsibility of the social services rather than of doctors spending a lot of time in administration. Otherwise, however, cannot the same principles apply—medical aid being given as required, with some specialisation within the rubric of psychiatry?

If it can be accepted that all doctors, some more than others, have a duty towards the mentally retarded this may be more successful than trying to expand the specialty of mental handicap. This has particular implications for training, which usually receives scant attention in any plans for the future. Much could be achieved by the use of rotational posts—in paediatrics, for example, in the departments of psychiatry and neurology, which are already involved in the care of these children, as well as in long-stay hospitals.

NEIL GORDON

Booth Hall Children's Hospital,
Manchester M9 2AA

Disinfection with glutaraldehyde

SIR,—The views expressed in Dr R M G Boucher's letter (1 December, p 1440) seem to be based on erroneous or incomplete data.

Firstly, Dr Boucher qualifies the statement made in his first letter (18 August, p 444) that "under normal hospital use the alkaline compositions have a short life (maximum 14 days)" by saying that "normal hospital use" means the use of Arbrook Cidematic machines. He claims that this accounts "for at least 60% of the Cidex market in US hospitals." In fact, Arbrook's data show that less than 10% of Cidex products are used in machines, while in the UK the figure is virtually nil. Thus the introduction of machine use into the argument appears to be something of a red herring and irrelevant to the central argument that alkaline glutaraldehydes can be as active as acid formulations over 28 days.

In this context, it is important to differentiate between Cidex Solution, a product with a proved 14-day use life¹ and Cidex Long-Life Solution (known as Cidex Formula 7 Solution in the USA), which has a proved 28-day use life.² While many users of Cidex in the UK only want a product to last 14 days, there are situations where under "normal" manual decontamination procedures Cidex Long-Life Solution is preferred because of its longer use life of 28 days. Such situations usually occur where use of Cidex is spasmodic and cost effectiveness is a prime consideration.

Dr Boucher further confuses the situation regarding shelf-storage life and stability of ready-to-use solutions. The shelf-storage life of the Cidex solutions before activation is essentially the same as that for Sonacide. After activation the Cidex products do lose glutaraldehyde slowly but they retain sufficient active ingredient to meet their label claims throughout their recommended use life under "normal use" conditions. "Normal use," as I have pointed out, is essentially manual decontamination using buckets and containers.

It is true, however, that there are conditions of high-dilution use where greater than 50% dilution can happen in less than 28 days, and this occurs mainly with the use of machines. Accordingly, we recommend a limitation on the use of Cidex Long-Life in machines to two weeks or 40 cycles. This has nothing to do with chemical stability, as indicated by Dr Boucher, but is purely a function of the physical dilution inherent in the use of machines. This limitation applies equally to acid glutaraldehyde solutions such as Sonacide.

Dr Boucher also omits to discuss the re-